The Japanese Nikkei 225 (JP225) index contract is extending yesterday's rebound by an additional 0.9%, approaching a bullish test of the 30-day exponential moving average (EMA30). Optimism in the Asian session is not only due to high expectations for de-escalation of the Middle East conflict following Donald Trump's comments but also excellent data providing hope for an economic recovery in Japan for the first time in a long while.
JP225 is currently sitting just below the EMA30 and the 38.2% Fibonacci retracement level of the latest downward wave, with a neutral RSI enabling further gains. While optimism based on Trump’s interviews remains fragile, Japan's fundamentals appear to have prospects for real improvement. Source: xStation5
What is driving JP225 today?
-
Donald Trump suggested a near end to war in Iran, emphasizing that U.S. progress is significantly further along than the 4-5 week plan prepared for the operation. Global markets immediately fell into euphoria; the US100 contract is gaining approximately 0.9%, and the VIX fear index is collapsing by 4.3%. All of Europe is also in the green (EU50: +0.8%).
-
The final reading of Japanese GDP for Q4 2025 was revised upward, erasing investor pessimism following the previous GDP pullback caused by the chaos of U.S. trade policy in 2025. Quarter-on-quarter growth was raised from a disappointing 0.1% to 0.3% (1.3% annualized growth).
-
The main driver was corporate capital expenditure (1.3% Q/Q vs. 0.2% forecast), as companies—following a period of solid results, subsiding uncertainty, and still-loose monetary policy—decided to allocate significantly more funds toward business development.
-
For the first time in over a year, an increase in real wages was also recorded (+1.4%), which translated into consumption growth among the Japanese (+0.3% Q/Q vs. 0.1% forecast). Large expenditures during the holiday season and general optimism regarding solutions proposed by Prime Minister Takaichi to lower the cost of living (e.g., 0% VAT on food or reduced energy fees) were also favorable.
Economic Calendar: NFP Data Overshadowed by the Holiday Break
Morning Wrap (03.04.2026)
Daily summary: Hopes for peace and space stocks in the spotlight
Globalstar: Are we headed for a battle of giants over orbit?
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
